Axsome Therapeutics Company Profile (NASDAQ:AXSM)

About Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics logoAxsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AXSM
  • CUSIP: N/A
  • Web:
  • Market Cap: $116.87 million
  • Outstanding Shares: 23,605,000
Average Prices:
  • 50 Day Moving Avg: $5.60
  • 200 Day Moving Avg: $4.62
  • 52 Week Range: $3.53 - $9.11
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.94
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.96 per share
  • Price / Book: 5.21
  • EBIDTA: ($28,750,000.00)
  • Return on Equity: -116.34%
  • Return on Assets: -74.68%
  • Debt-to-Equity Ratio: 0.35%
  • Current Ratio: 4.73%
  • Quick Ratio: 4.73%
  • Average Volume: 250,877 shs.
  • Beta: 0.93
  • Short Ratio: 4.52

Frequently Asked Questions for Axsome Therapeutics (NASDAQ:AXSM)

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced its earnings results on Wednesday, August, 9th. The company reported ($0.30) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.01. View Axsome Therapeutics' Earnings History.

When will Axsome Therapeutics make its next earnings announcement?

Axsome Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Axsome Therapeutics.

Where is Axsome Therapeutics' stock going? Where will Axsome Therapeutics' stock price be in 2017?

5 brokers have issued 12-month target prices for Axsome Therapeutics' stock. Their predictions range from $13.00 to $31.00. On average, they expect Axsome Therapeutics' stock price to reach $19.60 in the next twelve months. View Analyst Ratings for Axsome Therapeutics.

What are analysts saying about Axsome Therapeutics stock?

Here are some recent quotes from research analysts about Axsome Therapeutics stock:

  • 1. According to Zacks Investment Research, "Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc. is based in New York. " (7/13/2017)
  • 2. Aegis analysts commented, "We believe Ms. Potter’s prior experience adds value to the Board of Directors for Axsome. Her career in healthcare spans more than 30 years with multiple leadership positions at several large pharmaceutical companies. As Axsome looks to report multiple phase III interim analysis and topline readouts over the next 24 months, her experience in the commercialization process should go a long way for management. Myrtle Potter – Prior experience. After starting her career with Procter and Gamble Patient Care Products, Ms. Potter went on to spend 14 years of her early career at Merck & Co. While holding positions of increasing responsibility at Merck, she started Astra Merck, a joint venture entity that later became AstraZeneca, and served as Vice President of Merck’s US pharmaceutical business unit with about $800 mil revenue. Ms. Potter also served as President of Bristol-Myers Squibb’s US Cardiovascular and Metabolic Business – a 3,500 person business segment with $3.5 billion annual revenue – for 4 years. From 2000 to 2005 she was President, Commercial Operations and Chief Operating Officer at Genentech. While at Genentech, Ms. Potter led the commercialization of a long list of products: Herceptin, Tarceva, Xolair, Avastin, Rituxan, Nutropin, Activase, and TNkase." (6/20/2017)

Who are some of Axsome Therapeutics' key competitors?

Who are Axsome Therapeutics' key executives?

Axsome Therapeutics' management team includes the folowing people:

  • Herriot Tabuteau M.D., Chairman of the Board, Chief Executive Officer
  • John Golubieski, Chief Financial Officer
  • Constance Ames, Vice President - Finance
  • Mark Jacobson, Senior Director - Operations
  • Randall E. Kaye M.D., Chief Medical Officer
  • Robert Niecestro Ph.D., Head of Regulatory
  • Mark Coleman M.D., Independent Director
  • Roger A. Jeffs Ph.D., Independent Director
  • Myrtle S. Potter, Independent Director
  • Mark Saad, Independent Director

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

Who owns Axsome Therapeutics stock?

Axsome Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (7.38%), JPMorgan Chase & Co. (6.08%), Royce & Associates LP (3.73%), Sphera Funds Management LTD. (2.12%), Stifel Financial Corp (1.76%) and Vanguard Group Inc. (1.17%). View Institutional Ownership Trends for Axsome Therapeutics.

Who sold Axsome Therapeutics stock? Who is selling Axsome Therapeutics stock?

Axsome Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Northern Trust Corp, Vanguard Group Inc., FMR LLC and Mariner Wealth Advisors LLC. View Insider Buying and Selling for Axsome Therapeutics.

Who bought Axsome Therapeutics stock? Who is buying Axsome Therapeutics stock?

Axsome Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., LMR Partners LLP, Goldman Sachs Group Inc. and Susquehanna International Group LLP. View Insider Buying and Selling for Axsome Therapeutics.

How do I buy Axsome Therapeutics stock?

Shares of Axsome Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Axsome Therapeutics' stock price today?

One share of Axsome Therapeutics stock can currently be purchased for approximately $5.00.

MarketBeat Community Rating for Axsome Therapeutics (NASDAQ AXSM)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  136
MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Axsome Therapeutics (NASDAQ:AXSM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.60 (292.00% upside)

Analysts' Ratings History for Axsome Therapeutics (NASDAQ:AXSM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/26/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$28.00 -> $31.00HighView Rating Details
6/20/2017AegisReiterated RatingBuy$20.00HighView Rating Details
5/19/2017BTIG ResearchInitiated CoverageBuy$14.00HighView Rating Details
3/8/2017Cantor FitzgeraldSet Price TargetBuy$13.00LowView Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$20.00N/AView Rating Details
(Data available from 8/19/2015 forward)


Earnings History for Axsome Therapeutics (NASDAQ:AXSM)
Earnings by Quarter for Axsome Therapeutics (NASDAQ:AXSM)
Earnings History by Quarter for Axsome Therapeutics (NASDAQ AXSM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017($0.34)N/AView Earnings Details
8/9/2017Q2 2017($0.31)($0.30)ViewN/AView Earnings Details
5/9/20173/31/2017($0.40)($0.41)ViewN/AView Earnings Details
11/14/2016Q3($0.39)($0.38)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.39)($0.36)ViewN/AView Earnings Details
5/11/2016Q116($0.28)($0.31)ViewN/AView Earnings Details
3/24/2016Q416($0.22)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Axsome Therapeutics (NASDAQ:AXSM)
Current Year EPS Consensus Estimate: $-1.42 EPS
Next Year EPS Consensus Estimate: $-1.27 EPS


Dividend History for Axsome Therapeutics (NASDAQ:AXSM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Axsome Therapeutics (NASDAQ:AXSM)
Insider Ownership Percentage: 35.20%
Institutional Ownership Percentage: 32.69%
Insider Trades by Quarter for Axsome Therapeutics (NASDAQ:AXSM)
Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)
Insider Trades by Quarter for Axsome Therapeutics (NASDAQ:AXSM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/23/2015Randall KayeInsiderBuy1,000$9.03$9,030.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Axsome Therapeutics (NASDAQ:AXSM)
Latest Headlines for Axsome Therapeutics (NASDAQ:AXSM)
DateHeadline logoAxsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Recommendation of "Buy" from Analysts - August 12 at 2:32 AM logoAxsome Therapeutics, Inc. (AXSM) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS - August 10 at 3:42 PM logoAxsome Therapeutics Reports Second Quarter 2017 Financial Results - August 9 at 4:27 PM logoAxsome Therapeutics, Inc. (AXSM) to Release Quarterly Earnings on Monday - July 31 at 8:05 AM logoAxsome Therapeutics' (AXSM) Buy Rating Reaffirmed at Ladenburg Thalmann Financial Services - July 26 at 12:40 PM logoAxsome Therapeutics Announces AXS-06 (MoSEIC™ Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical Trial - July 25 at 4:09 PM logoAxsome Therapeutics, Inc. (AXSM) Given Average Rating of "Buy" by Brokerages - July 18 at 1:53 PM logoAxsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s Disease Agitation - July 17 at 4:37 PM logoAxsome Therapeutics, Inc. (AXSM) Downgraded by Zacks Investment Research to "Hold" - July 13 at 7:14 PM logoAxsome Therapeutics Appoints John Golubieski as Chief Financial Officer - July 6 at 7:38 AM logoWill Axsome Therapeutics (AXSM) Continue to Surge Higher? - June 22 at 11:55 AM logoAxsome Therapeutics, Inc. (AXSM) Upgraded at ValuEngine - June 21 at 10:38 PM logoAxsome Therapeutics, Inc. (AXSM) Receives Average Recommendation of "Buy" from Analysts - June 21 at 4:42 PM logoZacks: Axsome Therapeutics, Inc. (AXSM) Given Consensus Rating of "Strong Buy" by Brokerages - June 21 at 7:50 AM logoAxsome Therapeutics, Inc. (AXSM) Earns Buy Rating from Aegis - June 20 at 8:38 AM logoZacks Investment Research Upgrades Axsome Therapeutics, Inc. (AXSM) to "Buy" - June 19 at 5:04 PM logoAxsome Therapeutics Appoints Myrtle Potter to its Board of Directors - June 19 at 9:56 AM logoAxsome Therapeutics Inc (AXSM) Upgraded by Zacks Investment Research to "Buy" - June 5 at 4:22 PM logoAxsome Therapeutics Inc (AXSM) Stock Rating Lowered by Zacks Investment Research - June 2 at 6:18 PM logoAxsome Therapeutics Inc (AXSM) Lowered to Hold at Zacks Investment Research - May 26 at 4:40 PM logoAxsome Therapeutics Inc (AXSM) Receives "Buy" Rating from Aegis - May 25 at 7:48 AM logoAxsome Therapeutics Inc (AXSM) Upgraded to Buy at Zacks Investment Research - May 24 at 5:46 PM logoBTIG Research Initiates Coverage on Axsome Therapeutics Inc (AXSM) - May 19 at 9:34 AM logoAxsome Therapeutics Inc (AXSM) Forecasted to Post FY2017 Earnings of ($1.33) Per Share - May 15 at 8:52 AM logoAxsome Therapeutics Inc (AXSM) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - May 10 at 10:22 PM logoAxsome reports 1Q loss - May 9 at 9:56 AM logoAxsome Therapeutics Reports First Quarter 2017 Financial Results - May 9 at 9:05 AM logoAxsome Therapeutics (AXSM) Receives FDA Fast Track Designation for AXS-05 for AD Agitation - May 8 at 3:40 PM logoAxsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Alzheimer’s Disease Agitation - May 8 at 10:44 AM logoAxsome Therapeutics Inc (AXSM) to Release Earnings on Tuesday - May 7 at 7:12 AM logoAxsome Therapeutics (AXSM) Getting Positive News Coverage, Analysis Shows - May 4 at 7:58 AM logoShort Interest in Axsome Therapeutics Inc (AXSM) Rises By 69.5% - May 4 at 1:01 AM logoAxsome Therapeutics (AXSM) Earning Somewhat Favorable Press Coverage, Report Shows - May 1 at 12:42 PM logoAxsome Therapeutics (AXSM) Earning Positive News Coverage, Report Shows - April 27 at 4:42 PM logoAxsome Therapeutics (AXSM) Earns Daily Media Sentiment Rating of 0.01 - April 24 at 6:02 PM logoAxsome Therapeutics (AXSM) Earns Daily News Impact Score of 0.22 - April 19 at 7:47 AM logoAxsome Therapeutics (AXSM) Receiving Somewhat Positive Media Coverage, Report Finds - April 16 at 7:26 AM logoAxsome Therapeutics Inc (AXSM) Downgraded to "Hold" at Zacks Investment Research - March 24 at 7:22 PM logo Axsome Therapeutics Inc (AXSM) Given $20.33 Consensus Target Price by Brokerages - March 24 at 11:55 AM logoAxsome Therapeutics to Present at the 16th Annual Needham Healthcare Conference - March 23 at 4:12 PM logoCantor Fitzgerald Weighs in on Axsome Therapeutics Inc's FY2017 Earnings (AXSM) - March 23 at 9:32 AM logoAxsome Therapeutics Inc (AXSM) Stock Rating Reaffirmed by Aegis - March 23 at 8:53 AM logoAxsome Therapeutics (AXSM) Announces 3.74M Share Pricing at $3.74 - March 21 at 9:11 PM logoAxsome Therapeutics Announces Proposed Public Offering of Common Stock - March 21 at 4:09 PM logoAxsome Therapeutics Announces Pricing of Its Public Offering of Common Stock - March 21 at 12:26 PM logoAxsome Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update - March 8 at 1:50 AM logoAXSOME THERAPEUTICS, INC. Files SEC form 10-K, Annual Report - March 8 at 1:50 AM logoAxsome Therapeutics to Present at the 29th Annual ROTH Conference - March 7 at 9:32 AM logoAxsome Therapeutics (AXSM) Granted FDA Fast Track Status for AXS-05 - February 16 at 8:41 AM logoAXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits - February 14 at 8:20 PM



Axsome Therapeutics (AXSM) Chart for Saturday, August, 19, 2017

This page was last updated on 8/19/2017 by Staff